Risk Factors of First Thrombosis in Obstetric Antiphospholipid Syndrome

Overview

Journal Lupus Sci Med

Specialties Allergy & Immunology
Rheumatology

Date 2024 Jan 4

PMID 38176700

Authors

Liang Luo

Qingmeng Cai

Xiangjun Liu

Yuke Hou

Chun Li

Affiliations

Soon will be listed here.

Abstract

Objective: There is limited evidence on long-term thrombosis risk in patients with obstetric antiphospholipid syndrome (OAPS). This study aimed to investigate the clinical features and risk factors associated with the first thrombosis in patients with isolated OAPS.

Methods: Data from patients with isolated OAPS were collected. All patients were followed up until the first thrombotic event during or after delivery or until the end of the study. Logistic regression analysis identified independent risk factors associated with the first thrombosis in patients with isolated OAPS.

Results: The study enrolled 186 patients with OAPS. During a mean 5.4-year follow-up, 11 (5.9%) patients experienced thrombotic events. Multivariate binary logistic regression analysis revealed that triple-positive antiphospholipid antibodies (aPLs, OR=11.662, 95% CI=2.117 to 64.243, p=0.005) and hypocomplementemia (OR=9.047, 95% CI=1.530 to 53.495, p=0.015) were identified as independent risk factors for the first thrombosis in OAPS, after adjustment for low-dose aspirin and hydroxychloroquine.

Conclusions: Triple-positive aPLs and hypocomplementemia are risk factors for the first thrombosis in patients with OAPS.

Citing Articles

Understanding the Pathophysiology of Preeclampsia: Exploring the Role of Antiphospholipid Antibodies and Future Directions.

Mitranovici M, Chiorean D, Moraru R, Moraru L, Caravia L, Tiron A J Clin Med. 2024; 13(9).

PMID: 38731197 PMC: 11084819. DOI: 10.3390/jcm13092668.

References

Li C, Zuo Y, Zhang S, Makris U, Karp D, Li Z . Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients. Chin Med J (Engl). 2022; 135(6):658-664. PMC: 9276217. DOI: 10.1097/CM9.0000000000001964. View

Streiff M, Agnelli G, Connors J, Crowther M, Eichinger S, Lopes R . Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016; 41(1):32-67. PMC: 4715858. DOI: 10.1007/s11239-015-1317-0. View

Radin M, Schreiber K, Costanzo P, Cecchi I, Roccatello D, Baldovino S . The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. Int J Cardiol. 2017; 240:72-77. DOI: 10.1016/j.ijcard.2017.02.155. View

Alijotas-Reig J, Ferrer-Oliveras R, Esteve-Valverde E, Ruffatti A, Tincani A, Lefkou E . Inherited thrombophilia in women with poor aPL-related obstetric history: prevalence and outcomes. Survey of 208 cases from the European Registry on Obstetric Antiphospholipid Syndrome cohort. Am J Reprod Immunol. 2016; 76(2):164-71. DOI: 10.1111/aji.12534. View

Bala M, Paszek E, Lesniak W, Wloch-Kopec D, Jasinska K, Undas A . Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst Rev. 2018; 7:CD012534. PMC: 6513409. DOI: 10.1002/14651858.CD012534.pub2. View

Rand J, Wu X, Quinn A, Chen P, Hathcock J, Taatjes D . Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008; 112(5):1687-95. PMC: 2518879. DOI: 10.1182/blood-2008-03-144204. View

Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F . Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011; 118(17):4714-8. DOI: 10.1182/blood-2011-03-340232. View

Martinez-Zamora M, Peralta S, Creus M, Tassies D, Reverter J, Espinosa G . Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case-control study. Ann Rheum Dis. 2011; 71(1):61-6. DOI: 10.1136/ard.2011.153817. View

Niznik S, Rapoport M, Avnery O, Lubetsky A, Shavit R, Ellis M . Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome. Front Pharmacol. 2022; 13:824775. PMC: 9068935. DOI: 10.3389/fphar.2022.824775. View

10.

Sammaritano L, Bermas B, Chakravarty E, Chambers C, Clowse M, Lockshin M . 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020; 72(4):529-556. DOI: 10.1002/art.41191. View

11.

Kaiser R, Cleveland C, Criswell L . Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2008; 68(2):238-41. PMC: 2875136. DOI: 10.1136/ard.2008.093013. View

12.

de Jesus G, Sciascia S, Andrade D, Barbhaiya M, Tektonidou M, Banzato A . Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. BJOG. 2018; 126(5):656-661. PMC: 7382947. DOI: 10.1111/1471-0528.15469. View

13.

Udry S, Latino J, Belizna C, Wingeyer S, Romero D, de Larranaga G . A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome. Immunol Res. 2019; 67(6):478-485. DOI: 10.1007/s12026-019-09110-x. View

14.

Urbanus R, Siegerink B, Roest M, Rosendaal F, de Groot P, Algra A . Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009; 8(11):998-1005. DOI: 10.1016/S1474-4422(09)70239-X. View

15.

Chaturvedi S, Braunstein E, Yuan X, Yu J, Alexander A, Chen H . Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2019; 135(4):239-251. PMC: 6978159. DOI: 10.1182/blood.2019003863. View

16.

Arnaud L, Mathian A, Ruffatti A, Erkan D, Tektonidou M, Cervera R . Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2013; 13(3):281-91. DOI: 10.1016/j.autrev.2013.10.014. View

17.

Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x. View

18.

Lefevre G, Lambert M, Bacri J, Dubucquoi S, Quemeneur T, Caron C . Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients. Lupus. 2011; 20(8):861-5. DOI: 10.1177/0961203310397080. View

19.

Jiang H, Wang C, Jiang N, Li J, Wu C, Wang Q . Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study. Arthritis Res Ther. 2021; 23(1):138. PMC: 8105941. DOI: 10.1186/s13075-021-02515-w. View

20.

Garcia D, Erkan D . Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018; 378(21):2010-2021. DOI: 10.1056/NEJMra1705454. View